The association between neutropenia and prognosis in stage III colorectal cancer patients receiving adjuvant chemotherapy

European Journal of Cancer Care

Volumn 23, Issue 3, 2014, Pages 394-400

  Sunaga, T ^a,b   Suzuki, S ^a   Kogo, M ^b   Kurihara, T ^b   Kaji, S ^a   Koike, N ^a   Harada, N ^a   Suzuki, M ^a   Kiuchi, Y ^b  

^a Hachioji Digestive Disease Hospital   (Japan)

^b SHOWA UNIVERSITY   (Japan)

Author keywords

Adjuvant chemotherapy; Colorectal cancer; Neutropenia; Prognostic factor

Indexed keywords

ANTINEOPLASTIC AGENT; FOLINIC ACID; TEGAFUR; URACIL;

ADJUVANT CHEMOTHERAPY; ADULT; AGED; CANCER STAGING; CARCINOMA; CHEMICALLY INDUCED; COHORT ANALYSIS; COLORECTAL NEOPLASMS; FEMALE; HUMAN; MALE; MIDDLE AGED; NEUTROPENIA; PATHOLOGY; PROGNOSIS; PROPORTIONAL HAZARDS MODEL; RETROSPECTIVE STUDY; TREATMENT OUTCOME; VERY ELDERLY;

ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARCINOMA; CHEMOTHERAPY, ADJUVANT; COHORT STUDIES; COLORECTAL NEOPLASMS; FEMALE; HUMANS; LEUCOVORIN; MALE; MIDDLE AGED; NEOPLASM STAGING; NEUTROPENIA; PROGNOSIS; PROPORTIONAL HAZARDS MODELS; RETROSPECTIVE STUDIES; TEGAFUR; TREATMENT OUTCOME; URACIL;

EID: 84899494116     PISSN: 09615423     EISSN: 13652354     Source Type: Journal    
DOI: 10.1111/ecc.12120     Document Type: Article

References (25)

1. Berardi R., Braconi C., Mantello G., Scartozzi M., Del Prete S., Luppi G., Martinelli R., Fumagalli M., Valeri G., Bearzi I., Marmovale C., Grillö-Ruggieri F. & Cascinu S. (2006) Anemia may influence the outcome of patients undergoing neo-adjuvant treatment of rectal cancer. Annals of Oncology 17, 1661-1664.
2. Bonadonna G. & Valagussa P. (1981) Dose-response effect of adjuvant chemotherapy in breast cancer. The New England Journal of Medicine 304, 10-15.
3. Di Maio M., Gridelli C., Gallo C., Shepherd F., Piantedosi F.V., Cigolari S., Manzione L., Illiano A., Barbera S., Robbiati S.F., Frontini L., Piazza E., Ianniello G.P., Veltri E., Castiglione F., Rosetti F., Gebbia V., Seymour L., Chiodini P. & Perrone F. (2005) Chemotherapy-induced neutropenia and treatment efficacy in advanced non-small cell lung cancer: a pooled analysis of three randomised trials. The Lancet Oncology 6, 669-677.
4. Gurney H. (1996) Dose calculation of anticancer drugs: a review of the current practice and introduction of an alternative. Journal of Clinical Oncology 14, 2590-2611.
5. Gurney H. (2002) How to calculation the doseof chemotherapy. British Journal of Cancer 86, 1297-1302.
6. Ishitobi M., Komoike Y., Motomura K., Koyama H. & Inaji H. (2010) Prognostic significance of neutropenia on day one of anthracycline-based neoadjuvant chemotherapy in operable breast cancer. Oncology 78, 213-219.
7. Jemal A., Siegel R., Ward E., Hao Y., Xu J. & Thun M.J. (2009) Cancer statistics, 2009. CA: A Cancer Journal for Clinicians 59, 225-249.
8. Kim Y.H., Chung H.H., Kim J.W., Park N.H., Song Y.S. & Kang S.B. (2009) Prognostic significance of neutropenia during adjuvant concurrent chemoradiotherapy in early cervical cancer. Journal of Gynecologic Oncology 20, 146-150.
9. Kishida Y., Kawahara M., Teramukai S., Kubota K., Komuta K., Minato K., Mio T., Fujita Y., Yonei T., Nakano K., Tsuboi M., Shibata K., Atagi S., Kawaguchi T., Furuse K. & Fukushima M. (2009) Chemotherapy-induced neutropenia as a prognostic factor in advanced non-small-cell lung cancer: results from Japan multinational trial organization LC00-03. British Journal of Cancer 101, 1537-1542.
10. Labianca R., Nordlinger B., Beretta G.D., Brouquet A. & Cervantes A. (2010) Primary colon cancer: ESMO Clinical Practice Guidelines for diagnosis, adjuvant treatment and follow-up. Annals of Oncology 21, v70-v77.
11. Lembersky B.C., Wieand H.S., Petrelli N.J., O'connell M.J., Colangelo L.H., Smith R.E., Seay T.E., Giguere J.K., Marshall M.E., Jacobs A.D., Colman L.K., Soran A., Yothers G. & Wolmark N. (2006) Oral uracil and tegafur plus leucovorin compared with intravenous fluorouracil and leucovorin in stage II and III carcinoma of the colon: results from national surgical adjuvant breast and bowel project protocol C-06. Journal of Clinical Oncology 24, 2059-2064.
12. Locker G.Y., Hamilton S., Harris J., Jessup J.M., Kemeny N., Macdonald J.S., Somerfield M.R., Hayes D.F., Bast R.C. Jr & ASCO (2006) ASCO 2006 update of recommendations for the use of tumor markers in gastrointestinal cancer. Journal of Clinical Oncology 24, 5313-5327.
13. Matsuda T., Marugame T., Kamo K., Katanoda K., Ajiki W., Sobue T. & Japan Cancer Surveillance Research Group (2012) Based on data from 15 population-based cancer registries in the monitoring of cancer incidence in Japan (MCIJ) project. Japanese Journal of Clinical Oncology 42, 139-147.
14. Okazaki T., Javle M., Tanaka M., Abbruzzese J.L. & Li D. (2010) Single nucleotide polymorphisms of gemcitabine metabolic genes and pancreatic cancer survival and drug toxicity. Clinical Cancer Research 16, 320-329.
15. Parkin D.M., Bray F., Ferlay J. & Pisani P. (2005) Global cancer statistics, 2002. CA: A Cancer Journal for Clinicians 55, 74-108.
16. Poikonen P., Saarto T., Lundin J., Joensuu H. & Blomqvist C. (1999) Leucocyte nadir as a marker for chemotherapy efficacy in node-positive breast cancer treated with adjuvant CMF. British Journal of Cancer 80, 1763-1766.
17. Ratain M.J. (1998) Body-surface area as a basis for dosing of anticancer agents: science, myth, or habit? Journal of Clinical Oncology 16, 2297-2298.
18. Saarto T., Blomqvist C., Rissanen P., Auvinen A. & Elomaa I. (1997) Haematological toxicity: a marker of adjuvant chemotherapy efficacy in stage and breast cancer. British Journal of Cancer 75, 301-305.
19. Shitara K., Matsuo K., Takahari D., Yokota T., Inaba Y., Yamaura H., Sato Y., Najima M., Ura T. & Muro K. (2009) Neutropaenia as a prognostic factor in metastatic colorectal cancer patients undergoing chemotherapy with first-line FOLFOX. European Journal of Cancer 45, 1757-1763.
20. Shitara K., Matsuo K., Takahari D., Yokota T., Ura T., Ito S., Sawaki A., Tajika M., Kawai H. & Muro K. (2010) Neutropenia as a prognostic factor in advanced gastric cancer patients undergoing second-line chemotherapy with weekly paclitaxel. Annals of Oncology 21, 2403-2409.
21. Shitara K., Matsuo K., Oze I., Mizota A., Kondo C., Nomura M., Yokota T., Takahari D., Ura T. & Muro K. (2011) Meta-analysis of neutropenia or leucopenia as aprognostic factor in patients with malignant disease undergoing chemotherapy. Cancer Chemotherapy and Pharmacology 68, 301-307.
22. Sobin L.H. & Wittekind C., eds (2002) International Union Against Cancer. TNM Classification of Malignant Tumours, 6th edn. Springer, New York, USA.
23. Van Cutsem E. & Oliveira J. (2009) Primary colon cancer: ESMO clinical recommendations for diagnosis, adjuvant treatment and follow-up. Annals of Oncology 20 (Suppl. 4), 49-50.
24. Wolpin B.M., Meyerhardt J.A., Mamon H.J. & Mayer R.J. (2007) Adjuvant treatment of colorectal cancer. CA: A Cancer Journal for Clinicians 57, 168-185.
25. Yamanaka T., Matsumoto S., Teramukai S., Ishiwata R., Nagai Y. & Fukushima M. (2007) Predictive value of chemotherapy-induced neutropenia for the efficacy of oral fluoropyrimidine S-1 in advanced gastric carcinoma. British Journal of Cancer 97, 37-42.